Please assess the completion status of the following clinical trial:

Trial Title: The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Twelve (12) weeks or longer of two or more of the following signs and symptom consistent with chronic rhinosinusitis (CRS)~• mucopurulent drainage (anterior, posterior, or both), nasal obstruction (congestion),facial pain-pressure-fullness, and decreased sense of smell~AND inflammation documented by one or more of the following findings:~* purulent (not clear) mucus or edema in the middle meatus or ethmoid region,~* polyps in nasal cavity or the middle meatus, and/or~* radiographic imaging showing inflammation of the paranasal sinuses~Exclusion Criteria:~* Unable to speak English~* History of comorbid ciliary dyskinesia, cystic fibrosis or any other mucociliary condition~* Dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma and chronic obstructive pulmonary disease.~* History of oral or systematic antibiotic use in the past 2 weeks~* History of nasal or sinus surgery within past 6 weeks~* History of cerebrospinal fluid leak~* History of allergy to budesonide or other topical steroids~* Pregnant or breast feeding~* Current infection or history of one of the following infections: Tuberculosis (TB) lung infection, or Herpes infection of the eye.~* Baseline SNOT-22 total scores below 9 were excluded due to the inability to achieve a minimally clinically improved difference

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80.
- Saline Alone (Type: PLACEBO_COMPARATOR): Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).